by michaelhalassa | Jul 11, 2025 | Algorithmic psychiatry, Healthcare, Mental health treatment, muscarinic antipsychotic, Schizophrenia treatment
The recent Innovation in Psychosis Therapeutics Summit in Boston revealed a clear truth: while the field celebrates breakthroughs like muscarinic agents, it’s equally clear that psychiatric drug development needs a neuroscience reboot. We’ve mastered...
by michaelhalassa | Jul 10, 2025 | Computational psychiatry, Executive Control, Michael Halassa, Reinforcement learning, Schizophrenia
As a psychiatrist who treats patients with schizophrenia, I’ve long been struck by a fundamental puzzle: why do individuals with psychosis hold onto beliefs with such unwavering certainty, even when presented with compelling contradictory evidence? The answer,...
by michaelhalassa | May 14, 2025 | Cobenfy, KarXT
What Cobenfy Teaches Us About the Future of Psychiatric Drug Development The approval of Cobenfy (xanomeline-trospium) marks more than just the arrival of a new antipsychotic. It’s a signal—subtle but decisive—that the center of gravity in psychiatry may be shifting....
by michaelhalassa | May 14, 2025 | Schizophrenia
Schizophrenia, Circuits, and the Case for Neuromodulation In schizophrenia, the gap between what we know and what we can treat is wide. While dopamine-blocking drugs help with positive symptoms like delusions and hallucinations, they often leave patients...
by michaelhalassa | May 6, 2025 | Algorithmic psychiatry, Computational psychiatry, Mental health treatment, Schizophrenia treatment-resistant
Why Mental Health Treatments Need Algorithmic “Flight Simulators” I would like to highlight a recent perspective article that my colleagues and I have recently published: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00167-3 Despite...
